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Schistosomiasis, caused by infections with Schistosoma 
japonicum, is one of the human parasitic diseases that re-
mains a public health problem throughout the world’s trop-
ical and subtropical regions. With the sustained efforts for 
six decades, schistosomiasis has been effectively controlled 
in China. But in the lake region of the schistosomiasis en-
demic areas, the disease is still a big burden to some specif-
ic population, such as fishmen and boatmen, which hinders 
the local social-economic development. Currently, due to 
the low infection intensity in population of endemic areas 
after implementation of the integrated control strategy with 
multi-interventions [1], such as health education, preventive 
chemotherapy with praziquantel, mechanization in agricul-
ture with replacement of water buffalo, and snail elimina-
tion through environmental modification, sensitive diagnos-
tics still lack for detecting infections and assessing the ef-
fectiveness of the control interventions. Recently, The Lan-
cet Infectious Diseases published the findings from Chinese 
scientists that a single protein marker dramatically increased 
the sensitivity and specificity of immunodiagnostic testing 
of schistosome infection in humans [2]. 
This study was conducted by a research team led by Prof. 
Pan WeiQing, consisting of researchers from Tongji Uni-
versity School of Medicine, Jiangxi Provincial Institute of 
Parasitic Diseases, Medical College of Soochow University, 
and Second Military Medical University. The investigators 
carried out a genome-wide identification of diagnostic pro-
tein markers for schistosome infection and assessed their 
diagnostic validity in a field study. They predicted secreted 
proteins (SjSP) of S. japonicum was achieved through 
screening at genome-wide scale via bioinformatics tech-
nology. Briefly, the screening was performed based on the 
genome sequences along with the corresponding proteomic 
and transcriptomic datasets [3,4]. The putative secreted 
proteins were cloned and expressed as glutathione 
S-transferase fusion proteins (GST-SjSPs). The fusion pro-
teins were arrayed on GSH-immobilized microplates and 
screened with schistosomiasis patient sera. Only one re-
combinant protein (SjSP-13), out of 204, reacted to the en-
tire panel of 14 archived samples, although the other 35 
yielded seropositive reactions, eight showed strong immu-
noreactivity. The reactivity of SjSP-13 to 476 serum sam-
ples showed higher sensitivity (90.4%) and specificity 
(98.9%), based on laboratory evaluation [2].  
To understand the feasibility of the identified protein 
marker (SjSP-13) to be used in the national schistosomiasis 
control program, a field trial was carried out. The field trial 
was conducted in two villages which located in an endemic 
area of schistosomiasis in the south-eastern Poyang Lake, 
Jiangxi Province [2]. Of 1371 enrolled residents, only 74 
individuals were identified as being infected by traditional 
parasitological detection by using Kato-Katz thick smears, 
while 465 were diagnosed as positive by the SjSP-13-based 
ELISA kit (rSP13-ELISA). Of the 394 individuals found 
being egg-negative but rSP13-ELISA-positive, 363 (92.4%) 
were confirmed to be positive for schistosome infection by 
PCR detection of S. japonicum SjR2 retrotransposon (Fig-
ure 1). Furthermore, over 70% of the individuals showed 
seroconversion and all showed a dramatic decline of the 
anti-SjSP-13 antibody six months after chemotherapy, fur- 
ther demonstrating these individuals had a schistosome in-
fection.  
648 Zhou XN   Sci China Life Sci   June (2014) Vol.57 No.6 
 
Figure 1  Diagnostic methods used and the outcomes from a field study. Fecal samples from all the participants were examined by Kato-Katz test (27 slides 
from three samples per individual) and all serum samples were diagnosed by rSP13-ELISA. Samples that were rSP13-ELISA positive were further assayed 
by PCR for the SjR2 retrotransposon of Schistosoma japonicum.*53 samples diagnosed egg-positive and 50 samples diagnosed both egg and rSP13-ELISA 
negative were selected for PCR detection. 
Currently, the global schistosomiasis control program has 
made tremendous progress in terms of reducing the schis-
tosomiasis prevalence and morbidity in many endemic 
countries, particularly after the London Declaration on Ne-
glected Tropical Diseases. With the goal of the disease 
elimination, low but persistent levels of schistosomiasis 
transmission require essential changes in many aspects of 
elimination approaches [5]. For instance, the new tools of 
diagnosis and surveillance are urgent to be used in the local 
settings with low-intensity infections of hosts and in the 
evaluation of intervention effectiveness. The rSP13-ELISA 
tool developed by Dr. Xu and his colleagues showed sub-
stantial advantages over parasitological detection and 
SEA-ELISA, including adequate sensitivity and specificity 
needed in low transmission areas [2]. Application of this 
tool may allow identification of cases with low-intensity 
infections and targeted treatment.  
The National Schistosomiasis Control Program in China 
(2004–2015) was issued by Ministry of Health in 2004, with 
the aim of reducing the prevalence of schistosome infection 
in all endemic counties down to <5% by the end of 2008, 
and further down to 1% by the end of 2015 [6]. The success 
of this program and finally elimination of schistosomiasis in 
China hinges on the availability of sensitive, simple and 
affordable diagnostics to be used easily by staff at country 
level. In the field trial, it has been noticed that only 5% of 
the enrolled residents were identified as infected with 
schistosomes by Kato-Katz thick smears, while 33.9% were 
confirmed by virtue of a positive result from rSP13-ELISA 
[2]. According to the current control program, all infected 
individuals with S. japonicum have to be treated in order to 
eliminate the transmission. While the rSP13-ELISA ap-
proach developed in this study was particularly relevant for  
mild infections. It performed even better than SEA-ELISA 
as 89.9% of mild infections diagnosed correctly by the 
rSP13-ELISA kit compared to 79.9% by the SEA-ELISA 
kit [2]. Therefore, we recommend that further study on 
cut-off value of the kit is warrant, then it is not so difficult 
to translate this tool into control program in following three 
aspects: (i) screening for the treatment of targeted popula-
tion to achieve the transmission elimination, (ii) screening 
infected subjects in the surveillance system both in the 
pre-elimination and post-elimination stages, (iii) providing 
the certification tool in the elimination of schistosomiasis. 
Therefore, the research approach to discovery of SjSP-13 
protein marker as well as the product of rSP13-ELISA kit 
could contribute significantly to the elimination of schisto-
somiasis in China, eventually. 
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